Preventing olanzapine-induced weight gain using betahistine: A study in a rat model with chronic olanzapine treatment

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Lian, Jiamei ^a   Huang, Xu Feng ^a,b   Pai, Nagesh ^a   Deng, Chao ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPKALPHA PROTEIN; BETAHISTINE; HISTAMINE H1 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NUCLEAR FACTOR Y; OLANZAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROOPIOMELANOCORTIN; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; BENZODIAZEPINE DERIVATIVE; FAT DROPLET;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY HEIGHT; BODY WEIGHT DISORDER; BROWN ADIPOSE TISSUE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG REEXPOSURE; FAT MASS; FEMALE; FOOD INTAKE; HYPOTHALAMUS; LIPID STORAGE; LIVER WEIGHT; NONHUMAN; PROTEIN EXPRESSION; RAT; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FEEDING BEHAVIOR; LIVER; METABOLISM; OBESITY; ORGAN SIZE; PATHOLOGY; SPRAGUE DAWLEY RAT;

ADIPOSE TISSUE, BROWN; ADIPOSITY; ANIMALS; BENZODIAZEPINES; BETAHISTINE; DISEASE MODELS, ANIMAL; FEEDING BEHAVIOR; FEMALE; HYPOTHALAMUS; LIPID DROPLETS; LIVER; ORGAN SIZE; RATS, SPRAGUE-DAWLEY; WEIGHT GAIN;

EID: 84905455350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104160     Document Type: Article

References (77)

1. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. (2010) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 17: CD006654.
2. Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies. Eur Neuropsychopharmacol 21: 600-620.
3. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, et al. (2008) Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res 1211: 37-43.
4. Bustillo JR, Lauriello J, Parker K, Hammond R, Rowland L, et al. (2003) Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 28: 527-529.
5. Lieberman J, Stroup T, Swartz M (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223. (Pubitemid 41345943)
6. Depping AM, Komossa K, Kissling W, Leucht S (2010) Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 12: CD008120.
7. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, et al. (2009) Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophr Res 111: 9-16.
8. Nasrallah (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13: 27-35.
9. Correll CU, Lencz T, Malhotra AK (2011) Antipsychotic drugs and obesity. Trends Mol Med 17: 97-107.
10. Osuntokun O, Millen B, Xu WI, Kryzhanovskaya LA, Robertson-Plouch C, et al. (2011) Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics. J Psychopharmacol (Oxf) 25: 630-638.
11. Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, Berja A, Garcia-Unzueta MT, et al. (2008) Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Journal of Clinical Psychopharmacology 28: 289-295.
12. Stahl S, Meyer J, Mignon L (2009) Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 119: 171-179.
13. Deng C (2013) Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am 42: 545-563.
14. Correll CU (2010) From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 25, Supplement 2: S12-S21.
15. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7: 317-321. (Pubitemid 34280640)
16. Meltzer HY, Massey BW (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 11: 59-67.
17. Coccurello R, Moles A (2010) Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design. Pharmacol Ther 127: 210-251.
18. 3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry 34: 1-4.
19. 1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519-526.
20. Matsui-Sakata A, Ohtani H, Sawada Y (2005) Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 20: 368-378.
21. Weston-Green K, Huang X-F, Lian J, Deng C (2011) Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol 22: 364-373.
22. Remington G, Mann S, McCormick P, Nobrega JN, Hahn M, et al. (2011) Modeling chronic olanzapine exposure using osmotic minipumps: Pharmacological limitations. Pharmacol Biochem Behav 100: 86-89.
23. Kim DH, Maneen MJ, Stahl SM (2009) Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics 6: 78-85.
24. He M, Deng C, Huang XF (2013) The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs 27: 423-434.
25. 1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 104: 3456-3459.
26. Allison D, Mentore J, Heo M, Chandler L, Cappelleri J, et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696. (Pubitemid 29517559)
27. Vehof J, Risselada AJ, Al Hadithy AFY, Burger H, Snieder H, et al. (2011) Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology (Berl) 216: 257-265.
28. Davoodi N, Kalinichev M, Clifton PG (2008) Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat. Behav Pharmacol 19: 121-128 110.1097/FBP. 1090b1013e3282f1062c1066.
29. 1 receptor expression. Psychoneuroendocrinology 33: 569-580.
30. Sejima E, Yamauchi A, Nishioku T, Koga M, Nakagama K, et al. (2011) A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats. Cell Mol Neurobiol 31: 985-989.
31. Skrede S, Martins L, Berge RK, Steen VM, López M, et al. (2014) Olanzapine depot formulation in rat: A step forward in modelling antipsychotic-induced metabolic adverse effects. Int J Neuropsychopharmacol 17: 91-104.
32. He M, Zhang Q, Deng C, Wang H, Lian J, et al. (2014) Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats. Psychoneuroendocrinology 42: 153-164.
33. Souza RP, Tiwari AK, Chowdhury NI, Ceddia RB, Lieberman JA, et al. (2012) Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. J Psychiatr Res 46: 462-468.
34. Fernø J, Varela L, Skrede S, Vázquez MJ, Nogueiras R, et al. (2011) Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS ONE 6: e20571.
35. Weston-Green K, Huang XF, Deng C (2012) Alterations to Melanocortinergic GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine. PLoS ONE 7: e33548.
36. Zhang Q, He M, Deng C, Wang H, Lian J, et al. (2014) Hypothalamic ghrelin signalling mediates olanzapine induced hyperphagia and weight gain in female rats. Int J Neuropsychopharmacol 17.
37. Nedergaard J, Bengtsson T, Cannon B (2010) Three years with adult human brown adipose tissue. Ann N Y Acad Sci 1212: E20-36.
38. Cinti S (2006) The role of brown adipose tissue in human obesity. Nutr Metab Cardiovasc Dis 16: 569-574.
39. Zhang Q, Lian J, He M, Deng C, Wang H, et al. (2014) Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats. Prog Neuropsychopharmacol Biol Psychiatry 51: 172-180.
40. Stefanidis A, Verty ANA, Allen AM, Owens NC, Cowley MA, et al. (2008) The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity 17: 16-24.
41. Hu Y, Young AJ, Ehli EA, Nowotny D, Davies PS, et al. (2014) Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats. PLoS ONE 9: e93310.
42. Uldry M, Yang W, St-Pierre J, Lin J, Seale P, et al. (2006) Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab 3: 333-341.
43. Oh JE, Cho YM, Kwak SN, Kim JH, Lee KW, et al. (2012) Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics. Exp Mol Med 44: 545-553.
44. Sethi J, Sanchez-Alavez M, Tabarean IV (2012) Loss of histaminergic modulation of thermoregulation and energy homeostasis in obese mice. Neuroscience 217: 84-95.
45. Wan Z, Root-McCaig J, Castellani L, Kemp BE, Steinberg GR, et al. (2014) Evidence for the role of AMPK in regulating PGC-1 alpha expression and mitochondrial proteins in mouse epididymal adipose tissue. Obesity (Silver Spring) 22: 730-738.
46. Deng C, Lian J, Pai N, Huang XF (2012) Reducing olanzapine-induced weight gain side-effect by betahistine: a study in the rat model. J Psychopharmacol (Oxf) 26: 1291-1279.
47. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Weizman R, et al. (2013) Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology (Berl) 226: 615-622.
48. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, et al. (2007) Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl) 192: 441-448. (Pubitemid 46701583)
49. Jeck-Thole S, Wagner W (2006) Betahistine: a retrospective synopsis of safety data. Drug Saf 29: 1049-1059. (Pubitemid 44912713)
50. Deng C, Weston-Green KL, Han M, Huang X-F (2007) Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats. Prog Neuropsychopharmacol Biol Psychiatry 31: 915-920. (Pubitemid 46660303)
51. Weston-Green K, Huang X-F, Deng C (2011) Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res 217: 337-346.
52. Olds RJ, Olds JR (1979) A colour atlas of the rat : dissection guide London: Wolfe Medical.
53. Kwok AKH, Li WWY, Pang CP, Lai TYY, Yam GHF, et al. (2001) Indocyanine green staining and removal of internal limiting membrane in macular hole surgery: histology and outcome. Am J Ophthalmol 132: 178-183. (Pubitemid 32706511)
54. Maffulli N, Barrass V, Ewen SWB (2001) Light Microscopic Histology of Achilles Tendon Ruptures. The American Journal of Sports Medicine 28: 857-863.
55. Paxinos G, Watson C (2007) The rat brain in sterotaxic coordinates: Academic Press.
56. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, et al. (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085-1097. (Pubitemid 351418005)
57. Goudie AJ, Smith J, Halford J (2002) Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol (Oxf) 16: 291-296. (Pubitemid 35470572)
58. Pai N, Deng C, Vella SL, Castle D, Huang XF (2012) Are there different neural mechanisms responsible for three stages of weight gain development in antipsychotic therapy: temporally based hypothesis. Asian J Psychiatr 5: 315-318.
59. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, et al. (2009) Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long term weight course. J Psychiatr Res 43: 620-626.
60. Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A (2005) The effect of betahistine, a histamine H1 receptor agonist/H 3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol 20: 101-103. (Pubitemid 40354400)
61. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, et al. (2005) Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. The British Journal of Psychiatry 187: 537-543.
62. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. The FASEB Journal 22: 659-661. (Pubitemid 351348146)
63. Botta L, Mira E, Valli S, Zucca G, Benvenuti C, et al. (2001) Effects of betahistine and of its metabolites on vestibular sensory organs. Acta Otorhinolaryngol Ital 21: 24-30.
64. Fell MJ, Marshall KM, Williams J, Neill JC (2004) Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol (Oxf) 18: 149-155. (Pubitemid 38954901)
65. Cooper GD, Pickavance LC, Wilding JPH, Halford JCG, Goudie AJ (2005) A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181: 80-89. (Pubitemid 41440918)
66. Hillebrand JJG, de Wied D, Adan RAH (2002) Neuropeptides, food intake and body weight regulation: a hypothalamic focus. Peptides 23: 2283-2306. (Pubitemid 36092065)
67. Dalvi PS, Nazarians-Armavil A, Tung S, Belsham DD (2011) Immortalized Neurons for the Study of Hypothalamic Function. Am J Physiol Regul Integr Comp Physiol 300: R1030-1052.
68. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, et al. (1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374: 542-546.
69. Das C, Mendez G, Jagasia S, Labbate LA (2012) Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry 24: 225-239.
70. Richelson E (1996) Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 57: 4-11.
71. Correll C (2008) Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. International Review of Psychiatry 20: 195-201.
72. Lian J, Huang X-F, Pai N, Deng C (2010) Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 34: 1157-1158.
73. Martins PJF, Haas M, Obici S (2010) Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 59: 2418-2425.
74. Lopez M, Varela L, Vazquez MJ, Rodriguez-Cuenca S, Gonzalez CR, et al. (2010) Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 16: 1001-1008.
75. Morrison SF, Madden CJ, Tupone D (2014) Central Neural Regulation of Brown Adipose Tissue Thermogenesis and Energy Expenditure. Cell Metab 19: 741-756.
76. FDA (2005) Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. U.S. FDA Center for Drug Evaluation and Research.
77. Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20: 369-377. (Pubitemid 30449775)